Gapping down
In reaction to disappointing earnings/guidance: GBX -1.8%, MKC -1.1%
Select China related names showing weakness: JMEI -3.4%, JRJC -2%, SFUN -1.9%, CEA -1.9%, CMCM -0.7%
Select metals/mining stocks trading lower: HMY -1.5%, NEM -1.1%, GOLD -1.1%, SLV -0.9%, RIO -0.8%
Other news: XENE -35% (Xenon Pharmaceuticals and Teva (TEVA) Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain; TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints in Phase 2b study in pain due to osteoarthritis of the knee), BLDP -16.7% (prices its offering of 8,125,000 common shares at $1.60 per share), ACUR -11.4% (announces a private placement of 9.79 mln shares of common stock at $0.78/share), AXPW -2.3% (disclosed its 35-1 reverse split will be effective on July 14, 2015), WFD -0.9% (disclosed entry into an agreement to repurchase up to 711,733 shares of its common stock pursuant to its stock repurchase program)
Analyst comments: N/
A
In reaction to disappointing earnings/guidance: GBX -1.8%, MKC -1.1%
Select China related names showing weakness: JMEI -3.4%, JRJC -2%, SFUN -1.9%, CEA -1.9%, CMCM -0.7%
Select metals/mining stocks trading lower: HMY -1.5%, NEM -1.1%, GOLD -1.1%, SLV -0.9%, RIO -0.8%
Other news: XENE -35% (Xenon Pharmaceuticals and Teva (TEVA) Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain; TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints in Phase 2b study in pain due to osteoarthritis of the knee), BLDP -16.7% (prices its offering of 8,125,000 common shares at $1.60 per share), ACUR -11.4% (announces a private placement of 9.79 mln shares of common stock at $0.78/share), AXPW -2.3% (disclosed its 35-1 reverse split will be effective on July 14, 2015), WFD -0.9% (disclosed entry into an agreement to repurchase up to 711,733 shares of its common stock pursuant to its stock repurchase program)
Analyst comments: N/
A